Oxygen Biotherapeutics, Inc. Stock Nasdaq
Equities
US69207P2092
Biotechnology & Medical Research
End-of-day quote
Other stock markets
|
||
- USD | - |
Financials (USD)
Sales 2024 * | - | Sales 2025 * | - | Capitalization | 7.09M |
---|---|---|---|---|---|
Net income 2024 * | -19M | Net income 2025 * | -18M | EV / Sales 2024 * | - |
Net cash position 2024 * | - | Net cash position 2025 * | - | EV / Sales 2025 * | - |
P/E ratio 2024 * |
-0.44
x | P/E ratio 2025 * |
-0.97
x | Employees | - |
Yield 2024 * |
-
| Yield 2025 * |
-
| Free-Float | 99.65% |
Managers | Title | Age | Since |
---|---|---|---|
Chief Executive Officer | 50 | 21-07-13 | |
Director of Finance/CFO | 69 | Jan. 10 | |
Stuart Rich
CTO | Chief Tech/Sci/R&D Officer | 74 | 21-01-14 |
Members of the board | Title | Age | Since |
---|---|---|---|
Gerry Proehl
CHM | Chairman | 65 | 14-04-03 |
June Almenoff
BRD | Director/Board Member | 67 | 21-02-24 |
Declan Doogan
BRD | Director/Board Member | 72 | 21-02-24 |
1st Jan change | Capi. | |
---|---|---|
+64.23% | 55.07B | |
-2.31% | 41.79B | |
+44.36% | 40.22B | |
-8.29% | 28.17B | |
+11.97% | 26.28B | |
-21.16% | 18.93B | |
+7.54% | 13.03B | |
+27.17% | 12.26B | |
+25.72% | 12.21B |